Pharmacodynamics of antiinfective therapy: Taking what we know to the patient's bedside

Pharmacotherapy

Volumn 21, Issue 11 II, 2001, Pages

  Rodvold, K A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; LORACARBEF; MACROLIDE; METRONIDAZOLE; NETILMICIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG RESEARCH; DRUG SCREENING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS;

EID: 0034759941     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.18.319s.33904     Document Type: Conference Paper

References (80)

1. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
2. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
3. 1998 National clinical pharmacy services study
4. 1995 National clinical pharmacy services study
5. 1992 National clinical pharmacy services study
6. Pharmaceutical services in U.S. hospitals in 1989
7. National survey of extended-interval aminoglycoside dosing
8. National survey of once-daily dosing of aminoglycoside antibiotics
9. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
10. The future: Can we learn from the past?
11. Choosing an antibiotic on the basis of pharmacodynamics
12. The pharmacodynamics of beta-lactams
13. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
14. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study
15. In vitro activity and pharmacodynamics of oral β-lactam antibiotics against Streptococcus pneumoniae from Southeast Missouri
16. Streptococcus pneumoniae in the USA: In vitro susceptibility and pharmacodynamic analysis
17. Management of otitis media using Agency for Health Care Policy and Research guidelines
18. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis
19. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae
20. Continuous infusion of β-lactam antibiotics
21. Penicillin dosing for pneumococcal pneumonia
22. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology, and pharmacokinetics
23. Continuous infusion of β-lactam antibiotics
24. The pharmacodynamics of aminoglycosides
25. Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice
26. Daily dosages of aminoglycosides
27. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
28. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria
29. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms
30. Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety
31. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis
32. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses
33. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis
34. Single or multiple daily doses of aminoglycosides: A meta-analysis
35. Mega-analysis of meta-analysis: An examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials
36. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
37. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
38. Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review
39. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
40. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside
41. Single daily doses of aminoglycosides
42. Single daily dose of aminoglycosides: A concept whose time has not yet come
43. Single daily dosing of aminoglycosides: A community standard?
44. Once daily aminoglycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored?
45. Pharmacodynamics of fluoroquinolones
46. Pharmacokinetics and pharmacodynamics of fluoroquinolones
47. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
48. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute exacerbations of chronic bronchitis
49. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
50. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
51. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa
52. Antimicrobial action and pharmaco-kinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance
53. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
54. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
55. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae: Analysis of phase-III clinical trials
56. Application of fluoroquinolone pharmacodynamics
57. Antibiotic dosing issues in lower respiratory tract infection: Population-derived area under inhibitory curve is predictive of efficacy
58. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin
59. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae
60. Pharmaco-dynamic comparison of new fluoroquinolones against Streptococcus pneumoniae using Monte Carlo analysis
61. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection
62. Pharmacodynamics and pharmacokinetics of levofloxacin
63. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins
64. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
65. Clinical pharmacokinetics of clarithromycin
66. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers
67. Penetration of macrolides into pulmonary sites of infection
68. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
69. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
70. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin
71. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: Are we looking in the wrong place?
72. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects
73. Pharmacokinetic-pharmacodynamic modeling of irreversible drug effects
74. Dosing adjustments of 10 antimicrobials for patients with renal impairment
75. Oxazolidinones: A review
76. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection
77. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae
78. The selection of appropriate dosages for intravenous ciprofloxacin
79. A randomized open-label comparative trial of levofloxacin 750 mg once-daily versus IV ticarcillin/clavulanate with or without amoxicillin/clavulanate for the treatment of complicated skin and skin structure infections
80. Development of daptomycin for gram-positive infections